Accelerate Diagnostics, Inc.

NasdaqCM:AXDX Stock Report

Market Cap: US$29.1m

Accelerate Diagnostics Future Growth

Future criteria checks 0/6

Accelerate Diagnostics is forecast to grow revenue at 2.8% per annum. EPS is expected to grow by 18.4% per annum.

Key information

n/a

Earnings growth rate

18.4%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate2.8%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Apr 17
Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher

Accelerate Diagnostics spikes as Chief Technology Officer raises stake

Aug 30

Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Aug 20
Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics jumps 14% after beating Q2 estimates

Aug 15

Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Mar 15
Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022

Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022

Jan 04

Accelerate Diagnostics: An Investment Assessment

Sep 07

Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Feb 20
Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus

Jan 12

Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

Dec 29
Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years

Earnings and Revenue Growth Forecasts

NasdaqCM:AXDX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202512N/AN/AN/A1
12/31/202412N/AN/AN/A1
9/30/202412-53-27-27N/A
6/30/202412-38-33-32N/A
3/31/202412-59-37-35N/A
12/31/202312-62-41-40N/A
9/30/202312-63-43-42N/A
6/30/202312-80-48-47N/A
3/31/202313-66-50-49N/A
12/31/202213-62-49-49N/A
9/30/202213-71-52-51N/A
6/30/202213-64-51-50N/A
3/31/202212-67-48-47N/A
12/31/202112-78-48-47N/A
9/30/202112-74-46-46N/A
6/30/202112-84-47-46N/A
3/31/202111-81-47-46N/A
12/31/202011-78-52-50N/A
9/30/202012-81-55-54N/A
6/30/202010-82-60-59N/A
3/31/202010-84-64-63N/A
12/31/20199-84-65-65N/A
9/30/20198-85-66-65N/A
6/30/20197-87-66-66N/A
3/31/20197-89-71-71N/A
12/31/20186-88-69-68N/A
9/30/20186-82-68-67N/A
6/30/20185-77N/A-63N/A
3/31/20184-71N/A-56N/A
12/31/20174-64N/A-56N/A
9/30/20172-64N/A-55N/A
6/30/20171-64N/A-53N/A
3/31/20171-65N/A-56N/A
12/31/20160-66N/A-53N/A
9/30/20160-63N/A-50N/A
6/30/20160-57N/A-47N/A
3/31/20160-52N/A-41N/A
12/31/20150-45N/A-35N/A
9/30/20150-41N/A-30N/A
6/30/20150-39N/A-27N/A
3/31/20150-35N/A-22N/A
12/31/20140-31N/A-19N/A
9/30/20140-27N/A-17N/A
6/30/20140-22N/A-13N/A
3/31/20140-18N/A-11N/A
12/31/20130-15N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AXDX's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if AXDX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if AXDX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AXDX's revenue (2.8% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: AXDX's revenue (2.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AXDX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Accelerate Diagnostics, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sean LavinBTIG
Garrett NelsonCFRA Equity Research
Alexander NowakCraig-Hallum Capital Group LLC